AriBio’s Oral Alzheimer’s Drug Meets Monotherapy Goal in Phase 3; Fosun Considers Licensing

By Dr. Zubair Khalid, DVM, MS, PhD ·

AriBio’s Oral Alzheimer’s Drug Meets Monotherapy Goal in Phase 3; Fosun Considers Licensing

AriBio’s oral Alzheimer’s candidate mirodenafil, originally developed as an erectile dysfunction treatment, has met its monotherapy goal in a global phase 3 trial. The results were mixed overall, according to the company. Fosun Pharma holds an option to in-license the PDE5 inhibitor and is weighing whether to exercise it.

Mirodenafil is a PDE5 inhibitor, a class of drugs best known for treating erectile dysfunction. The phase 3 trial tested the drug as a monotherapy for Alzheimer’s disease. AriBio reported that the study achieved its primary endpoint, though the company has not released full details. Fosun’s potential licensing decision will depend on further evaluation of the data.

Context for the life sciences: The repurposing of existing drugs for new indications is a common strategy in biotech, particularly for complex diseases like Alzheimer’s. PDE5 inhibitors have drawn interest for their potential to improve blood flow and reduce neuroinflammation in the brain. If mirodenafil proves effective, it could offer an oral, at-home treatment option for Alzheimer’s, which currently has few approved therapies. The involvement of a major partner like Fosun also signals possible commercial interest in Asian markets.

Source: original report

Related articles